Search

Displaying results 4061 - 4070 of 10000 in total
  1. Drug

    Nisin Z

    go.drugbank.com/drugs/DB19122
    Investigational

    Nisin Z is under investigation in clinical trial NCT06097468 (Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)).

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.

  3. Drug

    Minaprine

    go.drugbank.com/drugs/DB00805
    Approved

    Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. … Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.

    Synonyms: N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine
  4. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  5. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  6. Drug

    Carbendazim

    go.drugbank.com/drugs/DB13009
    Investigational

    Carbendazim has been used in trials studying the treatment of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors. … ADH-1 is currently in clinical development in a combination program with a range of chemotherapeutic agents to investigate the synergistic effects noted in our preclinical models.

    Synonyms: l-cysteinamide, n-acetyl-l-cysteinyl-l-histidyl-l-alanyl-l-valyl-, cyclic (1-5)-disulfide
  8. Drug

    Smilagenin

    go.drugbank.com/drugs/DB05450
    Investigational

    in Parkinson’s disease. … P58 is a protein synthesis stimulant acts by restoring levels of proteins that are altered in the ageing brain, reversing the loss of nerve receptors in the ageing brain and potentially allowing for the

  9. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    It is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector

  10. Drug

    IDD-3

    go.drugbank.com/drugs/DB05427
    Experimental

    IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. … It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.